• Mutation; HGNC; HGNC:4390; GNAQ; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Unspecified (PubMed=22236444).
  

PubMed=16750193; DOI=10.1016/j.exer.2006.04.004
Nareyeck G., Zeschnigk M., Prescher G., Lohmann D.R., Anastassiou G.
Establishment and characterization of two uveal melanoma cell lines derived from tumors with loss of one chromosome 3.
Exp. Eye Res. 83:858-864(2006)

PubMed=19212147; DOI=10.1159/000201566
Nareyeck G., Zeschnigk M., Bornfeld N., Anastassiou G.
Novel cell lines derived by long-term culture of primary uveal melanomas.
Ophthalmologica 223:196-201(2009)

PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x; PMCID=PMC3288394
Griewank K.G., Yu X.-X., Khalili J.S., Sozen M.M., Stempke-Hale K., Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.
Genetic and molecular characterization of uveal melanoma cell lines.
Pigment Cell Melanoma Res. 25:182-187(2012)

PubMed=23849826; DOI=10.1016/j.ejca.2013.06.011
Amaro A., Mirisola V., Angelini G., Musso A., Tosetti F.I., Esposito A.I., Perri P., Lanza F.B., Nasciuti F., Mosci C., Puzone R., Salvi S., Truini M., Poggi A., Pfeffer U.
Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by gefitinib and cetuximab triggered antibody-dependent cellular cytotoxicity.
Eur. J. Cancer 49:3353-3365(2013)